Skip to content

TAG Public Comments for the AIDS Research Advisory Council (ARAC) Meeting, April 6, 2026: Renewing Funding for the HIV Clinical Trial Networks

  • Adam Ortega

TAG recommends that the AIDS Research Advisory Council (ARAC) endorse NIAID's continued support of a balanced and comprehensive portfolio of basic, clinical, and implementation science — including a funding opportunity to renew its four current networks: the Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG), the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT), the HIV Prevention Trials Network (HPTN), and the HIV Vaccine Trials Network (HVTN) or the updated IBPTN.

Read more

Near Point-of-Care TB Tests: What Communities Need to Know and Advocate for in Global Fund Grant Cycle 8

  • Adam Ortega

TB testing is getting faster, cheaper, and more accessible and advocates have a critical window to act. Treatment Action Group's new factsheet breaks down WHO-recommended near point-of-care TB tests and shows how communities can use Global Fund Grant Cycle 8 to finance their rollout. With an estimated 2.7 million people going undiagnosed in 2024 alone, the tools and funding are finally aligned. Now is the time to push for change.

Read more

Job Posting: Administrator

  • Jason Kirk

We're seeking a highly organized and technically proficient Administrator to support the organization as it continues to grow. This position reports to TAG’s Director of Finance. This is a full-time, salaried role.

Read more

World Tuberculosis Day 2026

  • Adam Ortega

On World TB Day, TAG is excited to share our most recent TB vaccine materials: a new TB vax-zine, community partnership report on emerging vaccines, supply chain analysis of adjuvants that boost vaccine effectiveness, and the most recent pipeline report on TB vaccines in development.

Read more

What TB Treatment Advocates Need to Know about aDSM/PV

  • Jason Kirk

Join TAG on April 16 at 8:30 a.m. ET for a practical webinar on drug safety monitoring in TB treatment. Learn how to identify side effects, support patient safety, and understand pharmacovigilance in the context of newer, all-oral DR-TB regimens.

Read more
Back To Top